In the dynamic realm of health tech startups, one name is swiftly climbing to prominence: Olutosin Alabi. This entrepreneur, born in Nigeria and currently pursuing an MBA at Syracuse University’s Whitman School of Management, is creating quite a stir with her groundbreaking approach to managing one of diabetes’ most persistent complications—foot ulcers.
Alabi’s brainchild, DiabeTech, stands on the brink of revolutionizing the $50 billion global diabetes care market with its AI-driven wearable technology. “We’re not merely developing a product,” Alabi asserts, “we’re sparking a movement toward empowering patients in the management of diabetes.”
DiabeTech’s innovative platform encompasses electronic tattoo sensors, sophisticated AI analytics, and an intuitive mobile app that collectively offer real-time monitoring and custom treatment advice for patients suffering from diabetic foot ulcers. This pioneering method has the potential to dramatically slash the $9.1 billion spent annually on diabetic foot ulcer treatment in the United States alone. “I see immense potential in this innovation,” Alabi enthuses. “DiabeTech fills a crucial void in diabetes care. With continuous monitoring and early intervention, we could potentially avert thousands of amputations each year.”
Alabi’s evolution from software engineer to health tech trailblazer is as remarkable as her cutting-edge product. Armed with a BSc in Computing from the University of Greenwich and an MSc in Information Technology from The Open University, Alabi merges technical prowess with a deft business sense, navigating the healthcare sector with finesse. Her entrepreneurial flair hasn’t gone unrecognized; Alabi first grabbed the spotlight in 2012 when she earned the Youth Enterprise with Innovation in Nigeria award, in partnership with the World Bank. This accolade set the stage for a flurry of subsequent honors, including the Bank of Industry Nigeria YES Grant in 2016 and the Tony Elumelu Foundation Business Award in 2018.
In 2024, Alabi continued her winning streak, securing business grants through the Afropreneur Competition and triumphing in the Raymond von Dran iPrize Competition. Her crowning achievement, however, came with her victory in the Whitman School of Management Dean’s Innovation Competition.
Sarah Johnson, a partner at eHealthTech Ventures, views Alabi as a rising star in the industry. “Olutosin epitomizes the potential of young entrepreneurs who blend technical acumen with a profound understanding of real-world problems,” Johnson observes. “Her consistent recognition in various competitions speaks volumes about her ability to disrupt the healthcare landscape.”
With the global digital health market expected to hit $639.4 billion by 2026, according to research from MarketsandMarkets, Alabi’s timing is impeccable. Olutosin Alabi is poised to not only revolutionize diabetic care but also to emerge as a formidable force in the health tech industry, propelled by a history of entrepreneurial success and widespread acclaim.
Media Contact:
Company Name: DiabeTech
Contact Person: Olutosin Alabi
Email: Send Email
Country: United States
Website: DiabeTech